• SUBSCRIBE
    • Action Alerts PLUS
    • Real Money
    • Real Money Pro
    • Quant Ratings
    • Retirement Daily
    • Stocks Under $10
    • Trifecta Stocks
    • Top Stocks
    • Real Money Pro Portfolio
    • Chairman's Club
    • Compare All
  • JIM CRAMER
    • Action Alerts PLUS
    • Cramer's Blog
    • Cramer's Monthly Call
    • Jim Cramer's Best Stocks
    • Cramer's Articles
    • Mad Money
    • 25 Rules for Investing
    • 10 Commandments
  • INVESTING
    • Bitcoin
    • Cannabis
    • Cryptocurrency
    • ETFs
    • Earnings
    • Fixed Income
    • Funds
      • Bond Funds
      • Index Funds
      • Mutual Funds
    • Futures
    • Options
    • REITs
    • Stocks
      • Penny Stocks
      • Preferred Stocks
  • PERSONAL FINANCE
    • Credit Cards
    • Debt Management
    • Education
    • Employee Benefits
    • Insurance
      • Car Insurance
      • Disability Insurance
      • Health Insurance
      • Home Insurance
      • Life Insurance
    • Mortgages
    • Real Estate
    • Savings
    • Taxes
  • RETIREMENT
    • 401K
    • Estate Planning
    • IRAs
      • Roth IRAs
    • Social Security
  • TECHNOLOGY
    • Cybersecurity
  • MARKETS
    • Bankruptcy
    • Commodities
      • Gold
      • Oil
    • Corporate Governance
    • Currencies
    • Emerging Markets
    • IPOs
    • Mergers and Acquisitions
    • Rates and Bonds
      • Junk Bonds
      • Treasury Bonds
    • Regulation
  • HOW-TO
  • VIDEO
    • Audio
  • Courses
    • Personal Finance Essentials
    • Fundamentals of Investing
  • Mavens on TheStreet
    • Biotech Maven
    • EconoMonitor
    • ETF Focus
    • FX@TheStreet with Cory Mitchell - Forex Trade Ideas
    • John Wall Street - Sports Business
    • Mish Talk - Global Economic Trends
    • Phil Davis - The Progressive Investor
    • Random Roger - ETF and Retirement
    • Stan The Annuity Man
    • Bull Market Fantasy with Jim Cramer
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
  • Privacy Settings
Logo
  • JIM CRAMER
  • INVESTING
  • PERSONAL FINANCE
  • RETIREMENT
  • TECHNOLOGY
  • MARKETS
  • HOW-TO
  • VIDEO
  • COURSES
Login
Account
TheStreet

Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Already have an account? Login here
  • Alerts
  • |
  • Newsletters
Logo
  • JIM CRAMER
  • INVESTING
  • PERSONAL FINANCE
  • RETIREMENT
  • TECHNOLOGY
  • MARKETS
  • HOW-TO
  • VIDEO
  • COURSES
Login
Account

Trade with Jim Cramer 14 Days Free

Join the Action Alerts PLUS Community today!

SUBSCRIBE NOW

LATEST NEWS

Coronavirus: Airfares From South Korea To China Shoot Up Amid Covid-19 Fears
Play
HEALTH

Coronavirus Updates: What's the Latest? A Timeline of Recent Events

  • By Steve Fiorillo
  • 14 hours ago
PRESS RELEASES

(FTSV) Alert: Johnson Fistel Investigates Proposed Sale Of Forty Seven, Inc.; Are Shareholders Getting A Fair Deal?

  • By PR Newswire
  • 21 hours ago
LinkedIn Tanks on Outlook; Gilead Sciences Crushes Expectations
MERGERS AND ACQUISITIONS

Gilead Sciences to Buy Cancer Drug Developer Forty Seven for $4.9 Billion

  • By M. Corey Goldman
  • 20 hours ago
PRESS RELEASES

Gilead To Acquire Forty Seven For $4.9 Billion

  • By Business Wire
  • 23 hours ago
Wall Street Preview: Investors Turn to Tech
MARKETS

Market Meltdown: How I’m Trading It and What the Fed, Treasury and SEC Should Do Now

  • By Stephen Guilfoyle
  • Feb 28, 2020 11:55 AM EST
Coronavirus Lead
INVESTING

Inovio Among Pharma Firms Prepping to Hit Go on Coronavirus Vaccine

  • By M. Corey Goldman
  • Feb 28, 2020 10:32 AM EST
Gilead Lead
INVESTING

Gilead Approaches Forty Seven With Takeover Offer

  • By Rob Lenihan
  • Feb 28, 2020 9:27 AM EST
Novavax CEO: Avian Flu Results Very Positive for Vaccine Maker
INVESTING

Novavax Begins Animal Testing for Coronavirus Vaccine Candidate

  • By Tony Owusu
  • Feb 27, 2020 11:11 AM EST
NYSE Stock Market Wall Street Trader
MARKETS

Dow Ends Down Nearly 1,200 Points as Wall Street's Awful Week Gets Worse

  • By Joseph Woelfel
  • Feb 27, 2020 4:32 PM EST
China's Capital Shrouded In Air Pollution Despite Reduced Emissions From Coronavirus Economic Slowdown
Video

Cure for Coronavirus: Are We There Yet?

  • Feb 27, 2020 8:33 AM EST
Trader New York Stock Exchange Lead
MARKETS

Microsoft, Coronavirus, Donald Trump, Gilead, Beyond Meat - 5 Things You Must Know Thursday

  • By Joseph Woelfel
  • Feb 27, 2020 7:58 AM EST
4. Gilead Sciences
INVESTING

Gilead Shares Gain After Launching Phase 3 Studies For Coronavirus Treatment

  • By Martin Baccardax
  • Feb 27, 2020 9:39 AM EST
PRESS RELEASES

Gilead Sciences Initiates Two Phase 3 Studies Of Investigational Antiviral Remdesivir For The Treatment Of COVID-19

  • By Business Wire
  • Feb 26, 2020 5:00 PM EST
NYSE Stock Market Wall Street Trader
MARKETS

Stocks End Mixed as Wall Street Assesses Virus Impact

  • By Joseph Woelfel
  • Feb 26, 2020 2:49 PM EST
China's Technology Start-ups Make A Spectacular Comeback From The Dog House Of The 2015 Stock Market Rout
JIM CRAMER

Coronavirus and Your Portfolio: Cramer's 'Mad Money' Recap (Tuesday 2/25/20)

  • By Scott Rutt
  • Feb 25, 2020 8:31 PM EST
Pedestrians pass a stock board of a securities firm in Tokyo on Monday, when shares tumbled in the few Asian markets open as China announced sharp increases in the number of people affected in the coronavirus outbreak. Photo: AP
Video

The Biggest Losers in Tuesday's Market Selloff

  • Feb 25, 2020 2:04 PM EST
Coronavirus: China Likely Overestimating Economic Recovery By Leaving Out Hard-hit Small Businesses
INVESTING

Moderna Surges After Shipping Coronavirus Vaccine for Human Trials

  • By Martin Baccardax
  • Feb 25, 2020 9:34 AM EST
Reality Confounds the Bears: Cramer's 'Mad Money' Recap (Wednesday 3/29/17)
JIM CRAMER

To Buy or to Sell?: Cramer's 'Mad Money' Recap (Monday 2/24/20)

  • By Scott Rutt
  • Feb 24, 2020 8:22 PM EST
Stock Market Traders Lead
Video

Biggest Stock Losers As Dow Declines 1,000 Points

  • Feb 24, 2020 3:03 PM EST
Trump Meets With Pharma Execs, but Jim Cramer Still Isn't Hot on the Sector
Video

Jim Cramer Explains How Investors Should Approach the Pharmaceutical Sector

  • Feb 24, 2020 1:42 PM EST
No Gilead Sciences M&A Yet, but CEO Offers Hint of Deals to Come
INVESTING

Bank of America Says Gilead's Remdesivir Offers 'Little Lasting' Profit Upside

  • By Tony Owusu
  • Feb 24, 2020 1:41 PM EST
Gilead Could Be Better off Splitting Drug Businesses -- RBC Capital
INVESTING

Gilead Rises Amid Spread of Coronavirus Outbreak - Here's the Trade

  • By Bret Kenwell
  • Feb 24, 2020 1:15 PM EST
4. Gilead Sciences
Video

Gilead Sciences — 3 Things We Still Need to Know

  • Feb 24, 2020 11:57 AM EST
Trader New York Stock Exchange Lead
MARKETS

Dow Ends Off 1,032; Stocks Slammed as Coronavirus Spreads Outside Asia

  • By Joseph Woelfel
  • Feb 24, 2020 2:32 PM EST
Gilead Lead
INVESTING

Gilead's Remdesivir May Be Effective Against Coronavirus, WHO Says

  • By Tony Owusu
  • Feb 24, 2020 10:05 AM EST
TheStreet
  • Terms Of Use
  • Privacy Policy
  • Advertise
  • Reprints
  • Customer Service
  • Data
  • Topic Archive
  • Subscriptions
© 2020 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.